Logo image
Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience
Journal article   Open access   Peer reviewed

Stereotactic Laser Ablation (SLA) followed by consolidation stereotactic radiosurgery (cSRS) as treatment for brain metastasis that recurred locally after initial radiosurgery (BMRS): a multi-institutional experience

Isabela Peña Pino, Jun Ma, Yusuke S Hori, Elena Fomchenko, Kathryn Dusenbery, Margaret Reynolds, Christopher Wilke, Jianling Yuan, Ethan Srinivasan, Matthew Grabowski, …
Journal of neuro-oncology, v 156(2), pp 295-306
2022
PMID: 35001245
url
https://doi.org/10.21203/rs.3.rs-794328/v1View

Abstract

Ablation Techniques Brain Neoplasms - pathology Brain Neoplasms - radiotherapy Brain Neoplasms - surgery Combined Modality Therapy Humans Laser Therapy - methods Neoplasm Recurrence, Local - radiotherapy Neoplasm Recurrence, Local - surgery Radiosurgery - methods Retrospective Studies Stereotaxic Techniques Treatment Outcome
The optimal treatment paradigm for brain metastasis that recurs locally after initial radiosurgery remains an area of active investigation. Here, we report outcomes for patients with BMRS treated with stereotactic laser ablation (SLA, also known as laser interstitial thermal therapy, LITT) followed by consolidation radiosurgery. Clinical outcomes of 20 patients with 21 histologically confirmed BMRS treated with SLA followed by consolidation SRS and > 6 months follow-up were collected retrospectively across three participating institutions. Consolidation SRS (5 Gy × 5 or 6 Gy × 5) was carried out 16-73 days (median of 26 days) post-SLA in patients with BMRS. There were no new neurological deficits after SLA/cSRS. While 3/21 (14.3%) patients suffered temporary Karnofsky Performance Score (KPS) decline after SLA, no KPS decline was observed after cSRS. There were no 30-day mortalities or wound complications. Two patients required re-admission within 30 days of cSRS (severe headache that resolved with steroid therapy (n = 1) and new onset seizure (n = 1)). With a median follow-up of 228 days (range: 178-1367 days), the local control rate at 6 and 12 months (LC , LC ) was 100%. All showed diminished FLAIR volume surrounding the SLA/cSRS treated BMRS at the six-month follow-up; none of the patients required steroid for symptoms attributable to these BMRS. These results compare favorably to the available literature for repeat SRS or SLA-only treatment of BMRS. This multi-institutional experience supports further investigations of SLA/cSRS as a treatment strategy for BMRS.

Metrics

6 Record Views
7 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Clinical Neurology
Oncology
Logo image